Screener
Royalty Pharma RPRX Loans and Lending Commitments
Loans and Lending Commitments at other companies
Other financials
Where this comes from
Reported directly by Royalty Pharma in its filing.
Tagged under the XBRL concept us-gaap:NotesReceivableNet.
The source filing: Royalty Pharma’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 9:02 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001802768-26-000015
| Line item | Estimated Royalty Duration(1) | As of June 30, 2026 / Gross Carrying Value | As of June 30, 2026 / Cumulative Allowance for Changes in Expected Cash Flows (Note 9) | As of June 30, 2026 / Net Carrying Value(4) |
|---|---|---|---|---|
| Voranigo | 2038 | 978,638 | — | 978,638 |
| Tysabri | (3) | 1,036,266 | (80,775) | 955,491 |
| Imdelltra | 2038-2041 | 937,842 | — | 937,842 |
| Tremfya | 2031-2032 | 901,427 | — | 901,427 |
| Other | 2026-2042 | 9,127,920 | (2,181,682) | 6,946,238 |
| Total | $20,117,632 | $(2,776,558) | $17,341,074 | |
| Less: Cumulative allowance for credit losses (Note 9) | (258,903) | |||
| Total current and non-current financial royalty assets, net | $17,082,171 |
Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FAQ
- What is Royalty Pharma's loans and lending commitments?
- Royalty Pharma (RPRX) reported loans and lending commitments of $17.08B in Q2 2026.
- How has Royalty Pharma's loans and lending commitments changed year-over-year?
- Royalty Pharma's loans and lending commitments increased by 6.9% year-over-year, from $15.98B to $17.08B.
- What is the long-term trend for Royalty Pharma's loans and lending commitments?
- Over 5 years (2020 to 2025), Royalty Pharma's loans and lending commitments has grown at a 5.7% compound annual growth rate (CAGR), from $12.96B to $17.06B.
- What does loans and lending commitments mean?
- Aggregate balance of loans and outstanding lending commitments.
Ask your AI about Royalty Pharma's loans and lending commitments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude